Tin tức & Cập nhật
Xem bài viết Ung thư
Xem
Chỉ hiển thị Multimedia
SONIA: Does 1L vs 2L use of CDK4/6 inhibitors improve OS in HR+, ERBB2- ABC?
24 Apr 2026
bởiNatalia Reoutova
A phase III randomized clinical trial (RCT) of 1,050 patients with hormone receptor–positive (HR-positive), ERBB2-negative advanced breast cancer (ABC) showed that first-line (1L) use of cyclin-dependent kinase (CDK) 4 and 6 inhibitors did not improve overall survival (OS) compared with second-line (2L) use. At the same time, a post hoc subgroup analysis suggested an OS benefit with 1L use of CDK4/6 inhibitors in premenopausal patients.
SONIA: Does 1L vs 2L use of CDK4/6 inhibitors improve OS in HR+, ERBB2- ABC?
24 Apr 2026
ROSELLA final analysis: 4-month OS increase with relacorilant in platinum-resistant ovarian cancer
23 Apr 2026
bởiNatalia Reoutova
The final overall survival (OS) analysis of the phase III ROSELLA clinical trial reports an increase of 4.1 months in median OS in patients with platinum-resistant ovarian cancer who received relacorilant in addition to nab-paclitaxel vs those who received nab-paclitaxel alone.
